SAB Biotherapeutics (SABS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

SABS Stock Forecast

SAB Biotherapeutics stock forecast is as follows: an average price target of $5.67 (represents a 21.94% upside from SABS’s last price of $4.65) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

SABS Price Target

The average price target for SAB Biotherapeutics (SABS) is $5.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $3.00. This represents a potential 21.94% upside from SABS's last price of $4.65.

SABS Analyst Ratings

Buy

According to 5 Wall Street analysts, SAB Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SABS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

SAB Biotherapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 07, 2024	Kumaraguru Raja	Loop Capital Markets	$8.00	$2.84	181.69%	72.04%
Apr 02, 2024	Edward White	H.C. Wainwright	$6.00	$4.29	39.86%	29.03%
Aug 11, 2022		Chardan Capital	$3.00	$1.12	167.86%	-35.48%

The latest SAB Biotherapeutics stock forecast, released on Jun 07, 2024 by Kumaraguru Raja from Loop Capital Markets, set a price target of $8.00, which represents a 181.69% increase from the stock price at the time of the forecast ($2.84), and a 72.04% increase from SABS last price ($4.65).

SAB Biotherapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$7.00
Last Closing Price	$4.65	$4.65	$4.65
Upside/Downside	-100.00%	-100.00%	50.54%

In the current month, the average price target of SAB Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SAB Biotherapeutics's last price of $4.65. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 09, 2024	Craig-Hallum		Buy	Initialise
Aug 27, 2024	Oppenheimer		Outperform	Initialise
Jun 07, 2024	Brookline Capital		Buy	Initialise
Apr 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 11, 2022	Chardan Capital	Buy	Buy	Hold
May 13, 2022	Chardan Capital	Buy	Buy	Hold

SAB Biotherapeutics's last stock rating was published by Craig-Hallum on Oct 09, 2024. The company Initialise its SABS rating from "null" to "Buy".

SAB Biotherapeutics Financial Forecast

SAB Biotherapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	$1.27M	$85.52K	$581.10K	$2.16M	$3.59M	$6.35M	$11.80M	$60.88M	-
Avg Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$333.33K	$333.33K	$333.33K	$333.33K	$120.00K	$120.00K	$263.14K	$11.97K	$400.00K	$2.54M	$5.90M	$6.85M	$10.80M	$11.47M	$16.90M	$14.40M
High Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$333.33K	$333.33K	$333.33K	$333.33K	$120.00K	$120.00K	$263.14K	$11.98K	$400.00K	$2.54M	$5.90M	$6.85M	$10.80M	$11.47M	$16.90M	$17.28M
Low Forecast	$500.00K	$500.00K	$500.00K	$500.00K	$333.33K	$333.33K	$333.33K	$333.33K	$120.00K	$120.00K	$263.14K	$11.95K	$400.00K	$2.54M	$5.90M	$6.85M	$10.80M	$11.47M	$16.90M	$11.52M
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	1	1	1	4	4	7	5	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	105.91%	0.21%	0.23%	0.37%	0.52%	0.59%	1.03%	3.60%	-

SAB Biotherapeutics's average Quarter revenue forecast for Jun 24 based on 1 analysts is $263.14K, with a low forecast of $263.14K, and a high forecast of $263.14K. SABS's average Quarter revenue forecast represents a -79.24% decrease compared to the company's last Quarter revenue of $1.27M (Sep 23).

SAB Biotherapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	1	1	1	4	4	7	5	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-4.23M	$-6.48M	$-6.42M	$-7.80M	$-6.88M	$-5.75M	$-6.02M	$-11.52M	$-337.35K
Avg Forecast	$-249.96K	$-249.96K	$-249.96K	$-249.96K	$-166.64K	$-166.64K	$-166.64K	$-166.64K	$-59.99K	$-59.99K	$-147.87K	$-5.98K	$-199.97K	$-1.27M	$-2.95M	$-3.85M	$-6.07M	$-6.44M	$-9.50M	$-539.75K
High Forecast	$-249.96K	$-249.96K	$-249.96K	$-249.96K	$-166.64K	$-166.64K	$-166.64K	$-166.64K	$-59.99K	$-59.99K	$-147.87K	$-5.97K	$-199.97K	$-1.27M	$-2.95M	$-3.85M	$-6.07M	$-6.44M	$-9.50M	$-431.80K
Low Forecast	$-249.96K	$-249.96K	$-249.96K	$-249.96K	$-166.64K	$-166.64K	$-166.64K	$-166.64K	$-59.99K	$-59.99K	$-147.87K	$-5.99K	$-199.97K	$-1.27M	$-2.95M	$-3.85M	$-6.07M	$-6.44M	$-9.50M	$-647.70K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	706.44%	32.39%	5.06%	2.64%	1.79%	0.95%	0.93%	1.21%	0.63%

undefined analysts predict SABS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than SAB Biotherapeutics's previous annual EBITDA (undefined) of $NaN.

SAB Biotherapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	1	1	1	4	4	7	5	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-5.10M	$-6.88M	$-7.40M	$-7.87M	$-6.34M	$-4.78M	$985.86K	$-17.88M	$-326.11K
Avg Forecast	$-8.43M	$-8.15M	$-7.87M	$-7.59M	$-6.27M	$-6.23M	$-6.11M	$-8.27M	$-10.78M	$-10.24M	$-10.61M	$-10.80M	$-12.96M	$-10.49M	$-9.03M	$-13.27M	$-12.03M	$-13.27M	$-8.02M	$-529.33K
High Forecast	$-8.43M	$-8.15M	$-7.87M	$-7.59M	$-6.27M	$-6.23M	$-6.11M	$-8.27M	$-9.65M	$-10.24M	$-10.61M	$-10.80M	$-12.96M	$-10.49M	$-9.03M	$-13.27M	$-12.03M	$-13.27M	$-8.02M	$-423.46K
Low Forecast	$-8.43M	$-8.15M	$-7.87M	$-7.59M	$-6.27M	$-6.23M	$-6.11M	$-8.27M	$-12.18M	$-10.24M	$-10.61M	$-10.80M	$-12.96M	$-10.49M	$-9.03M	$-13.27M	$-12.03M	$-13.27M	$-8.02M	$-635.19K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.47%	0.53%	0.70%	0.87%	0.48%	0.40%	-0.07%	2.23%	0.62%

SAB Biotherapeutics's average Quarter net income forecast for Jun 22 is $-12.03M, with a range of $-12.03M to $-12.03M. SABS's average Quarter net income forecast represents a -1320.41% decrease compared to the company's last Quarter net income of $985.86K (Mar 22).

SAB Biotherapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	1	1	1	4	4	7	5	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	$2.57M	$2.90M	$3.45M	$2.88M	$4.04M	$4.31M	$5.19M	$17.09M	-
Avg Forecast	$1.12M	$1.12M	$1.12M	$1.12M	$749.02K	$749.02K	$749.02K	$749.02K	$269.65K	$269.65K	$591.29K	$26.89K	$898.83K	$5.71M	$13.26M	$15.39M	$24.27M	$25.77M	$37.97M	$32.36M
High Forecast	$1.12M	$1.12M	$1.12M	$1.12M	$749.02K	$749.02K	$749.02K	$749.02K	$269.65K	$269.65K	$591.29K	$26.93K	$898.83K	$5.71M	$13.26M	$15.39M	$24.27M	$25.77M	$37.97M	$38.83M
Low Forecast	$1.12M	$1.12M	$1.12M	$1.12M	$749.02K	$749.02K	$749.02K	$749.02K	$269.65K	$269.65K	$591.29K	$26.85K	$898.83K	$5.71M	$13.26M	$15.39M	$24.27M	$25.77M	$37.97M	$25.89M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	95.60%	3.23%	0.60%	0.22%	0.26%	0.18%	0.20%	0.45%	-

SAB Biotherapeutics's average Quarter SG&A projection for Jun 24 is $591.29K, based on 1 Wall Street analysts, with a range of $591.29K to $591.29K. The forecast indicates a -77.00% fall compared to SABS last annual SG&A of $2.57M (Sep 23).

SAB Biotherapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	1	1	1	1	1	4	4	7	5	11
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.10	$-0.14	$-0.15	$-0.18	$-0.15	$-0.11	$0.02	$-0.41	$-0.09
Avg Forecast	$-0.91	$-0.88	$-0.85	$-0.82	$-0.68	$-0.67	$-0.66	$-0.89	$-1.16	$-1.11	$-1.15	$-1.17	$-1.40	$-1.13	$-0.97	$-1.43	$-1.30	$-1.43	$-0.87	$1.25
High Forecast	$-0.91	$-0.88	$-0.85	$-0.82	$-0.68	$-0.67	$-0.66	$-0.89	$-1.04	$-1.11	$-1.15	$-1.17	$-1.40	$-1.13	$-0.97	$-1.43	$-1.30	$-1.43	$-0.87	$1.25
Low Forecast	$-0.91	$-0.88	$-0.85	$-0.82	$-0.68	$-0.67	$-0.66	$-0.89	$-1.32	$-1.11	$-1.15	$-1.17	$-1.40	$-1.13	$-0.97	$-1.43	$-1.30	$-1.43	$-0.87	$1.25
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.08%	0.10%	0.13%	0.18%	0.10%	0.08%	-0.01%	0.47%	-0.08%

According to 4 Wall Street analysts, SAB Biotherapeutics's projected average Quarter EPS for Jun 22 is $-1.30, with a low estimate of $-1.30 and a high estimate of $-1.30. This represents a -6600.00% decrease compared to SABS previous annual EPS of $0.02 (Mar 22).

SAB Biotherapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PCSA	Processa Pharmaceuticals	$1.01	$9.00	791.09%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
CVKD	Cadrenal Therapeutics	$11.45	$32.00	179.48%	Buy
THRD	Third Harmonic Bio	$11.35	$20.00	76.21%	Buy
SABS	SAB Biotherapeutics	$4.03	$5.67	40.69%	Buy
MNPR	Monopar Therapeutics	$30.68	$29.50	-3.85%	Buy

SABS Forecast FAQ

Is SAB Biotherapeutics a good buy?

Yes, according to 5 Wall Street analysts, SAB Biotherapeutics (SABS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of SABS's total ratings.

What is SABS's price target?

SAB Biotherapeutics (SABS) average price target is $5.67 with a range of $3 to $8, implying a 21.94% from its last price of $4.65. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will SAB Biotherapeutics stock go up soon?

According to Wall Street analysts' prediction for SABS stock, the company can go up by 21.94% (from the last price of $4.65 to the average price target of $5.67), up by 72.04% based on the highest stock price target, and down by -35.48% based on the lowest stock price target.

Can SAB Biotherapeutics stock reach $7?

SABS's highest twelve months analyst stock price target of $8 supports the claim that SAB Biotherapeutics can reach $7 in the near future.

What are SAB Biotherapeutics's analysts' financial forecasts?

SAB Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.33M (high $1.33M, low $1.33M), average EBITDA is $-667K (high $-667K, low $-667K), average net income is $-26.882M (high $-26.882M, low $-26.882M), average SG&A $3M (high $3M, low $3M), and average EPS is $-2.903 (high $-2.903, low $-2.903). SABS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2M (high $2M, low $2M), average EBITDA is $-1M (high $-1M, low $-1M), average net income is $-32.037M (high $-32.037M, low $-32.037M), average SG&A $4.49M (high $4.49M, low $4.49M), and average EPS is $-3.46 (high $-3.46, low $-3.46).

Did the SABS's actual financial results beat the analysts' financial forecasts?

Based on SAB Biotherapeutics's last annual report (Dec 2022), the company's revenue was $23.9M, which missed the average analysts forecast of $35.02M by -31.74%. Apple's EBITDA was $-27.159M, beating the average prediction of $-19.313M by 40.63%. The company's net income was $-18.741M, missing the average estimation of $-47.59M by -60.62%. Apple's SG&A was $16.38M, missing the average forecast of $78.69M by -79.18%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-5.142 by -91.64%. In terms of the last quarterly report (Sep 2023), SAB Biotherapeutics's revenue was $1.27M, beating the average analysts' forecast of $11.97K by 10491.35%. The company's EBITDA was $-4.226M, beating the average prediction of $-5.982K by 70544.08%. SAB Biotherapeutics's net income was $-5.102M, missing the average estimation of $-10.802M by -52.77%. The company's SG&A was $2.57M, beating the average forecast of $26.89K by 9460.27%. Lastly, the company's EPS was $-0.0974, missing the average prediction of $-1.167 by -91.65%